YONKERS, N.Y., Jan. 8 /PRNewswire-FirstCall/ -- Advanced Viral Research
Corp. (OTC Bulletin Board: ADVR) today announced that it has been awarded U.S.
Patent Number 6.670,118 entitled "Method for Treating Papillomavirus
Infections". The patent describes the use of AVR118 (previously known as
Product R) for the topical treatment of patients suffering with lesions
resulting from human papillomavirus (HPV) infections, including genital warts.
ADVR has completed a Phase I clinical trial in the U.S. to evaluate the
safety of topical application of AVR118 in healthy volunteers. There were no
local adverse reactions to the application of AVR118 to the skin of these
subjects. The Company is now planning Phase II trials for the topical use of
AVR118.
HPV is a common world-wide sexually transmitted infection (STI). The
American Social Health Association estimates there are approximately 5.5
million new cases of sexually transmitted HPV infections reported each year
and at least 20 million Americans are infected.
The most common clinical manifestation of HPV is warts which are benign
tumors. The most common infections caused by strains of HPV are digital and
plantar warts -- warts on the hands and feet, commonly seen in children.
These warts represent one of the most prevalent dermatologic infections
worldwide. Several strains of HPV are associated with the appearance of
cervical cancer which is one of the most common malignancies infecting women.
Some 500,000 cases of invasive cervical cancer are diagnosed worldwide each
year. In developing nations, cervical cancer is the most common female
malignancy, accounting for 24% of all cancers in women. In developed
countries, cervical cancer ranks behind cancer of the breast, lung, uterus and
ovaries, accounting for some 7% of all cancers in women.
Patients suffering with immunodeficiencies, such as patients with AIDS,
are particularly susceptible to infection with HPV. Disseminated HPV
in.fection is one of the opportunistic infections complicating AIDS and is
manifested by eruption of generalized, often very painful warts over the body.
At present, there is no specific and satisfactory therapy for disseminated HPV
infection in AIDS patients.
"Use of AVR118 in the treatment of HPV infection is a potentially
significant contribution of AVR118 to the therapy of a prevalent and
troublesome viral infection that is responsible for much morbidity over the
world. The potential of AVR118 as a therapy for disseminated HPV infection in
patients with AIDS merits further clinical study," said James T. D'Olimpio
M.D., a clinical consultant to ADVR.
ADVR's AVR118 represents a biopolymer chemistry that possesses novel
immunomodulator activity. This peptide-nucleic acid, which to date has shown
no indication of human toxicity, appears to stimulate the proinflammatory
responses required to combat viral infections such as AIDS and human
papillomavirus and to dampen aberrant autoimmune-type inflammatory responses,
such as occur in patients with rheumatoid arthritis. AVR118 is in clinical
trials in Israel for the treatment of cachexia (body wasting) in patients with
AIDS.
For further information regarding Advanced Viral Research Corp., please
visit our website at http://www.adviral.com. Advanced Viral Research Corp., based in
Yonkers, New York, is a biopharmaceutical firm dedicated to improving
patients' lives by researching, developing and bringing to market new and
effective therapies for viral and other diseases.
Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company. AVR118 (Product R)
is not approved by the U.S. Food and Drug Administration or any comparable
agencies of any other countries. There is no assurance that the Company will
be able to secure the financing necessary to continue and/or complete the
clinical trials of AVR118 or satisfy certain other conditions relating to
clinical trials including obtaining adequate insurance on terms acceptable to
the Company or that if completed, clinical trials performed outside the United
States will assist the Company in obtaining FDA or other regulatory approval.
The Company undertakes no obligation to update or revise the information
contained in this announcement whether as a result of new information, future
events or circumstances or otherwise.
Contact: Ronnie Welch or
Kelly Cinelli
CWR & Partners
508/222-4802
SOURCE Advanced Viral Research Corp.
 back to top
Related links:
http://www.adviral.com
Company News On-Call:
http://www.prnewswire.com/comp/903002.html
CONTACT:
Ronnie Welch, or Kelly Cinelli,
+1-508-222-4802, both of CWR & Partners, for Advanced Viral
Research Corp.
|
